Bioengineering and the diabetic foot ulcer
AbstractDiabetic disease is increasing exponentially on a global scale. Diabetic foot ulcers (DFUs) are the leading cause of nontraumatic lower limb amputations. The pathophysiological events need to be considered when designing new interventions. Bioengineered skin substitutes (BSS) are accepted in the therapeutic armamentarium for DFU treatment. However, newer designs are likely to offer more targeted approaches to the disease process. This relates to the stimulation of vasculogenesis in particular. This can be achieved by using interactive scaffolds that stimulate endothelial progenitor cells to increase vascular endothelial growth factor production and reverse some of the damage that is caused by glycation end-products that are characteristic of diabetes.
By submitting manuscripts to WHSA, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in WHSA for educational and research purposes without obtaining permission.